Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:33:51.159Z.
Calculation as of: 2026-10-06T17:33:51.159Z.
Quote observation: 2026-10-06T17:30:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 772026cfaa68636964238f2a0be34d7b7ee81ab44c33f4f711fca00153048be4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.42B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Price/OCF Ratio
26.42
TTM Avg
22.09
3Y Avg
27.32
5Y Avg
28.27
Market Cap
$1.41B
Price/OCF Ratio
77.95
TTM Avg
254.68
3Y Avg
254.68
5Y Avg
167.20
Market Cap
$1.45B
Price/OCF Ratio
9.21
TTM Avg
9.60
3Y Avg
21.94
5Y Avg
276.98
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.42B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | N/A | 7.14 | 7.14 | 7.14 |
| Certara, Inc. (CERT)vs › | $1.43B | 17.31 | 12.61 | 22.38 | 32.95 |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 26.42 | 22.09 | 27.32 | 28.27 |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 77.95 | 254.68 | 254.68 | 167.20 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 9.21 | 9.60 | 21.94 | 276.98 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
